{
  "trial_id": "NCT00194714",
  "trial_group": "cancer",
  "generated-by-gpt4-omni-zs": {
    "gen-response": "Age, gender, race, ECOG performance status, HER2 overexpression status, HLA-A2 status, hematocrit level, platelet count, white blood cell count, creatinine level, creatinine clearance, serum bilirubin level, serum glutamic-oxaloacetic transaminase (SGOT) level, left ventricular ejection fraction (LVEF), prior treatments, concurrent hormonal therapy, concurrent biphosphonate therapy, presence of major infections or surgical procedures, cardiac disease history, autoimmune disease status, immunodeficiency disorder status.",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "gender"
        ]
      ],
      "remaining_reference_features": [
        "Categorical",
        "Male",
        "Ethnicity (NIH/OMB)",
        "Race (NIH/OMB)",
        "Region of Enrollment"
      ],
      "remaining_candidate_features": [
        "race",
        "ECOG performance status",
        "HER2 overexpression status",
        "HLA-A2 status",
        "hematocrit level",
        "platelet count",
        "white blood cell count",
        "creatinine level",
        "creatinine clearance",
        "serum bilirubin level",
        "serum glutamic-oxaloacetic transaminase (SGOT) level",
        "left ventricular ejection fraction (LVEF)",
        "prior treatments",
        "concurrent hormonal therapy",
        "concurrent biphosphonate therapy",
        "presence of major infections or surgical procedures",
        "cardiac disease history",
        "autoimmune disease status",
        "immunodeficiency disorder status"
      ]
    }
  },
  "generated-by-gpt4-omni-ts": {
    "gen-response": "Age, Continuous, Sex: Female, Male, Race/Ethnicity, Customized, Region of Enrollment, ECOG performance status, HER2 overexpression status, HLA-A2 status, Hematocrit, Platelet count, White blood cells (WBC), Creatinine, Serum bilirubin, Serum glutamic-oxaloacetic transaminase (SGOT), Left ventricular ejection fraction (LVEF), ",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "Sex: Female"
        ],
        [
          "Male",
          "Male"
        ],
        [
          "Race (NIH/OMB)",
          "Race/Ethnicity"
        ],
        [
          "Region of Enrollment",
          "Region of Enrollment"
        ]
      ],
      "remaining_reference_features": [
        "Categorical",
        "Ethnicity (NIH/OMB)"
      ],
      "remaining_candidate_features": [
        "ECOG performance status",
        "HER2 overexpression status",
        "HLA-A2 status",
        "Hematocrit",
        "Platelet count",
        "White blood cells (WBC)",
        "Creatinine",
        "Serum bilirubin",
        "Serum glutamic-oxaloacetic transaminase (SGOT)",
        "Left ventricular ejection fraction (LVEF)"
      ]
    }
  },
  "generated-by-llama3-70b-in-ts": {
    "gen-response": "Age, Continuous, Sex: Female, Male, Race/Ethnicity, Customized, Region of Enrollment, Cancer Type (Breast or Ovarian), HER2 Status, HLA-A2 Status, ECOG Performance Status, Trastuzumab Treatment Duration, Prior Chemotherapy, Prior Radiation Therapy, Prior Hormonal Therapy, Prior Immunotherapy, LVEF at Baseline, Hematocrit at Baseline, Platelet Count at Baseline, WBC at Baseline, Creatinine at Baseline, Bilirubin at Baseline, SGOT at Baseline.",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "Sex: Female"
        ],
        [
          "Male",
          "Male"
        ],
        [
          "Race (NIH/OMB)",
          "Race/Ethnicity"
        ],
        [
          "Region of Enrollment",
          "Region of Enrollment"
        ]
      ],
      "remaining_reference_features": [
        "Categorical",
        "Ethnicity (NIH/OMB)"
      ],
      "remaining_candidate_features": [
        "Cancer Type (Breast or Ovarian)",
        "HER2 Status",
        "HLA-A2 Status",
        "ECOG Performance Status",
        "Trastuzumab Treatment Duration",
        "Prior Chemotherapy",
        "Prior Radiation Therapy",
        "Prior Hormonal Therapy",
        "Prior Immunotherapy",
        "LVEF at Baseline",
        "Hematocrit at Baseline",
        "Platelet Count at Baseline",
        "WBC at Baseline",
        "Creatinine at Baseline",
        "Bilirubin at Baseline",
        "SGOT at Baseline"
      ]
    }
  },
  "generated-by-llama3-70b-in-zs": {
    "gen-response": "Age, sex, race, ECOG performance status, cancer type (breast or ovarian), HER2 expression level, HLA-A2 status, prior cancer treatment, trastuzumab treatment duration, concurrent hormonal therapy, concurrent biphosphonate therapy, hematocrit, platelet count, white blood cell count, creatinine level, bilirubin level, SGOT level, left ventricular ejection fraction.",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "sex"
        ],
        [
          "Race (NIH/OMB)",
          "race"
        ]
      ],
      "remaining_reference_features": [
        "Categorical",
        "Male",
        "Ethnicity (NIH/OMB)",
        "Region of Enrollment"
      ],
      "remaining_candidate_features": [
        "ECOG performance status",
        "cancer type (breast or ovarian)",
        "HER2 expression level",
        "HLA-A2 status",
        "prior cancer treatment",
        "trastuzumab treatment duration",
        "concurrent hormonal therapy",
        "concurrent biphosphonate therapy",
        "hematocrit",
        "platelet count",
        "white blood cell count",
        "creatinine level",
        "bilirubin level",
        "SGOT level",
        "left ventricular ejection fraction"
      ]
    }
  }
}